Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

Survey on PD Patients With Depressive Symptoms

1 sierpnia 2014 zaktualizowane przez: Boehringer Ingelheim

BI_Sifrol Tablets Special Drug Use Surveillance(Survey on the Safety and Efficacy in Parkinson's Disease Patients With Depressive Symptoms)

The primary objective of this investigation is to conduct a 12-week prospective survey in PD patients with depressive symptoms treated with BI Sifrol Tablets (hereinafter referred to as this drug) in the routine clinical settings to determine the following items related to the safety and efficacy.

i. Adverse drug reaction symptoms, incidence, and severity ii. Motor capacity during the investigation iii. Depressive symptoms during the investigation

Przegląd badań

Status

Zakończony

Warunki

Typ studiów

Obserwacyjny

Zapisy (Rzeczywisty)

1089

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Lokalizacje studiów

  • Japonia
      • Akashi, Japonia
        • Boehringer Ingelheim Investigational Site
      • Akita, Japonia
        • Boehringer Ingelheim Investigational Site 1
      • Akita, Japonia
        • Boehringer Ingelheim Investigational Site 2
      • Asahikawa, Japonia
        • Boehringer Ingelheim Investigational Site
      • Ashikaga, Japonia
        • Boehringer Ingelheim Investigational Site
      • Awaji, Japonia
        • Boehringer Ingelheim Investigational Site
      • Chitose, Japonia
        • Boehringer Ingelheim Investigational Site
      • Chuo, Japonia
        • Boehringer Ingelheim Investigational Site
      • Fuchu, Japonia
        • Boehringer Ingelheim Investigational Site 1
      • Fuchu, Japonia
        • Boehringer Ingelheim Investigational Site 2
      • Fuefuki, Japonia
        • Boehringer Ingelheim Investigational Site
      • Fuehuki, Japonia
        • Boehringer Ingelheim Investigational Site
      • Fujioka, Japonia
        • Boehringer Ingelheim Investigational Site
      • Fujisaki, Japonia
        • Boehringer Ingelheim Investigational Site
      • Fujisawa, Japonia
        • Boehringer Ingelheim Investigational Site
      • Fukaya, Japonia
        • Boehringer Ingelheim Investigational Site
      • Fukuoka, Japonia
        • Boehringer Ingelheim Investigational Site 1
      • Fukuoka, Japonia
        • Boehringer Ingelheim Investigational Site 2
      • Fukuoka, Japonia
        • Boehringer Ingelheim Investigational Site 3
      • Fukuoka, Japonia
        • Boehringer Ingelheim Investigational Site 4
      • Fukuoka, Japonia
        • Boehringer Ingelheim Investigational Site 5
      • Fukushima, Japonia
        • Boehringer Ingelheim Investigational Site 1
      • Fukushima, Japonia
        • Boehringer Ingelheim Investigational Site 2
      • Funabashi, Japonia
        • Boehringer Ingelheim Investigational Site
      • Gifu, Japonia
        • Boehringer Ingelheim Investigational Site 1
      • Gifu, Japonia
        • Boehringer Ingelheim Investigational Site 2
      • Habikino, Japonia
        • Boehringer Ingelheim Investigational Site
      • Hachioji, Japonia
        • Boehringer Ingelheim Investigational Site
      • Hamamatsu, Japonia
        • Boehringer Ingelheim Investigational Site 1
      • Hamamatsu, Japonia
        • Boehringer Ingelheim Investigational Site 2
      • Hamamatsu, Japonia
        • Boehringer Ingelheim Investigational Site 3
      • Hamamatsu, Japonia
        • Boehringer Ingelheim Investigational Site 4
      • Hamamatsu, Japonia
        • Boehringer Ingelheim Investigational Site 5
      • Hanamaki, Japonia
        • Boehringer Ingelheim Investigational Site
      • Hayashima, Japonia
        • Boehringer Ingelheim Investigational Site
      • Higashiosaka, Japonia
        • Boehringer Ingelheim Investigational Site 1
      • Higashiosaka, Japonia
        • Boehringer Ingelheim Investigational Site 2
      • Himeji, Japonia
        • Boehringer Ingelheim Investigational Site
      • Hirakata, Japonia
        • Boehringer Ingelheim Investigational Site
      • Hirishima, Japonia
        • Boehringer Ingelheim Investigational Site
      • Hirosaki, Japonia
        • Boehringer Ingelheim Investigational Site
      • Ibaragi, Japonia
        • Boehringer Ingelheim Investigational Site
      • Iizuka, Japonia
        • Boehringer Ingelheim Investigational Site
      • Inag, Japonia
        • Boehringer Ingelheim Investigational Site
      • Irima, Japonia
        • Boehringer Ingelheim Investigational Site
      • Isahaya, Japonia
        • Boehringer Ingelheim Investigational Site
      • Iwaki, Japonia
        • Boehringer Ingelheim Investigational Site
      • Iwamizawa, Japonia
        • Boehringer Ingelheim Investigational Site
      • Iwata, Japonia
        • Boehringer Ingelheim Investigational Site
      • Jyoetsu, Japonia
        • Boehringer Ingelheim Investigational Site 1
      • Jyoetsu, Japonia
        • Boehringer Ingelheim Investigational Site 2
      • Jyoyo, Japonia
        • Boehringer Ingelheim Investigational Site
      • Kagoshima, Japonia
        • Boehringer Ingelheim Investigational Site 1
      • Kagoshima, Japonia
        • Boehringer Ingelheim Investigational Site 2
      • Kagoshima, Japonia
        • Boehringer Ingelheim Investigational Site 3
      • Kahoku, Japonia
        • Boehringer Ingelheim Investigational Site
      • Kamakura, Japonia
        • Boehringer Ingelheim Investigational Site
      • Kanazawa, Japonia
        • Boehringer Ingelheim Investigational Site 1
      • Kanazawa, Japonia
        • Boehringer Ingelheim Investigational Site 2
      • Kanoya, Japonia
        • Boehringer Ingelheim Investigational Site 1
      • Kanoya, Japonia
        • Boehringer Ingelheim Investigational Site 2
      • Kashihara, Japonia
        • Boehringer Ingelheim Investigational Site 1
      • Kashihara, Japonia
        • Boehringer Ingelheim Investigational Site 2
      • Kasuga, Japonia
        • Boehringer Ingelheim Investigational Site
      • Kawagchi, Japonia
        • Boehringer Ingelheim Investigational Site
      • Kawaguchi, Japonia
        • Boehringer Ingelheim Investigational Site
      • Kawasaki, Japonia
        • Boehringer Ingelheim Investigational Site 1
      • Kawasaki, Japonia
        • Boehringer Ingelheim Investigational Site 2
      • Kitakami, Japonia
        • Boehringer Ingelheim Investigational Site
      • Kiyose, Japonia
        • Boehringer Ingelheim Investigational Site 1
      • Kiyose, Japonia
        • Boehringer Ingelheim Investigational Site 2
      • Kodaira, Japonia
        • Boehringer Ingelheim Investigational Site
      • Kofu, Japonia
        • Boehringer Ingelheim Investigational Site
      • Koga, Japonia
        • Boehringer Ingelheim Investigational Site
      • Komae, Japonia
        • Boehringer Ingelheim Investigational Site
      • Komatsu, Japonia
        • Boehringer Ingelheim Investigational Site
      • Komatsushima, Japonia
        • Boehringer Ingelheim Investigational Site
      • Koriyama, Japonia
        • Boehringer Ingelheim Investigational Site 1
      • Koriyama, Japonia
        • Boehringer Ingelheim Investigational Site 2
      • Koshigaya, Japonia
        • Boehringer Ingelheim Investigational Site
      • Kumamoto, Japonia
        • Boehringer Ingelheim Investigational Site 1
      • Kumamoto, Japonia
        • Boehringer Ingelheim Investigational Site 2
      • Kumamoto, Japonia
        • Boehringer Ingelheim Investigational Site 3
      • Kure, Japonia
        • Boehringer Ingelheim Investigational Site
      • Kusatsu, Japonia
        • Boehringer Ingelheim Investigational Site
      • Kyoto, Japonia
        • Boehringer Ingelheim Investigational Site 1
      • Kyoto, Japonia
        • Boehringer Ingelheim Investigational Site 2
      • Kyoto, Japonia
        • Boehringer Ingelheim Investigational Site 3
      • Kyoto, Japonia
        • Boehringer Ingelheim Investigational Site 4
      • Maebashi, Japonia
        • Boehringer Ingelheim Investigational Site
      • Matsudo, Japonia
        • Boehringer Ingelheim Investigational Site
      • Matsumoto, Japonia
        • Boehringer Ingelheim Investigational Site
      • Mibu, Japonia
        • Boehringer Ingelheim Investigational Site
      • Mihara, Japonia
        • Boehringer Ingelheim Investigational Site
      • Mihoro, Japonia
        • Boehringer Ingelheim Investigational Site
      • Miriyama, Japonia
        • Boehringer Ingelheim Investigational Site
      • Misato, Japonia
        • Boehringer Ingelheim Investigational Site
      • Miyako, Japonia
        • Boehringer Ingelheim Investigational Site
      • Miyazaki, Japonia
        • Boehringer Ingelheim Investigational Site 1
      • Miyazaki, Japonia
        • Boehringer Ingelheim Investigational Site 2
      • Moriguchi, Japonia
        • Boehringer Ingelheim Investigational Site
      • Morioka, Japonia
        • Boehringer Ingelheim Investigational Site 1
      • Morioka, Japonia
        • Boehringer Ingelheim Investigational Site 2
      • Moriya, Japonia
        • Boehringer Ingelheim Investigational Site
      • Musashino, Japonia
        • Boehringer Ingelheim Investigational Site
      • Nagano, Japonia
        • Boehringer Ingelheim Investigational Site
      • Nagaoka, Japonia
        • Boehringer Ingelheim Investigational Site
      • Nagaokakyo, Japonia
        • Boehringer Ingelheim Investigational Site
      • Nagoya, Japonia
        • Boehringer Ingelheim Investigational Site 1
      • Nagoya, Japonia
        • Boehringer Ingelheim Investigational Site 2
      • Nagoya, Japonia
        • Boehringer Ingelheim Investigational Site 3
      • Nagoya, Japonia
        • Boehringer Ingelheim Investigational Site 4
      • Nara, Japonia
        • Boehringer Ingelheim Investigational Site 1
      • Nara, Japonia
        • Boehringer Ingelheim Investigational Site 2
      • Narashino, Japonia
        • Boehringer Ingelheim Investigational Site
      • Narita, Japonia
        • Boehringer Ingelheim Investigational Site
      • Naruto, Japonia
        • Boehringer Ingelheim Investigational Site
      • Nasushiobara, Japonia
        • Boehringer Ingelheim Investigational Site
      • Nichinan, Japonia
        • Boehringer Ingelheim Investigational Site
      • Ninohe, Japonia
        • Boehringer Ingelheim Investigational Site
      • Nishinomiya, Japonia
        • Boehringer Ingelheim Investigational Site
      • Nishitokyo, Japonia
        • Boehringer Ingelheim Investigational Site
      • Ogaki, Japonia
        • Boehringer Ingelheim Investigational Site
      • Oiso, Japonia
        • Boehringer Ingelheim Investigational Site
      • Oita, Japonia
        • Boehringer Ingelheim Investigational Site 1
      • Oita, Japonia
        • Boehringer Ingelheim Investigational Site 2
      • Oita, Japonia
        • Boehringer Ingelheim Investigational Site 3
      • Okaya, Japonia
        • Boehringer Ingelheim Investigational Site
      • Okayama, Japonia
        • Boehringer Ingelheim Investigational Site 1
      • Okayama, Japonia
        • Boehringer Ingelheim Investigational Site 2
      • Okazaki, Japonia
        • Boehringer Ingelheim Investigational Site
      • Okinawa, Japonia
        • Boehringer Ingelheim Investigational Site
      • Omura, Japonia
        • Boehringer Ingelheim Investigational Site
      • Omuta, Japonia
        • Boehringer Ingelheim Investigational Site
      • Onojyo, Japonia
        • Boehringer Ingelheim Investigational Site
      • Osaka, Japonia
        • Boehringer Ingelheim Investigational Site 1
      • Osaka, Japonia
        • Boehringer Ingelheim Investigational Site 2
      • Osaka, Japonia
        • Boehringer Ingelheim Investigational Site 3
      • Osaka, Japonia
        • Boehringer Ingelheim Investigational Site 4
      • Osaka, Japonia
        • Boehringer Ingelheim Investigational Site 5
      • Osaka, Japonia
        • Boehringer Ingelheim Investigational Site 6
      • Ota, Japonia
        • Boehringer Ingelheim Investigational Site
      • Otake, Japonia
        • Boehringer Ingelheim Investigational Site
      • Otsu, Japonia
        • Boehringer Ingelheim Investigational Site
      • Ryugasaki, Japonia
        • Boehringer Ingelheim Investigational Site
      • Saeki, Japonia
        • Boehringer Ingelheim Investigational Site
      • Saga, Japonia
        • Boehringer Ingelheim Investigational Site
      • Sagamihara, Japonia
        • Boehringer Ingelheim Investigational Site 1
      • Sagamihara, Japonia
        • Boehringer Ingelheim Investigational Site 2
      • Sagamihara, Japonia
        • Boehringer Ingelheim Investigational Site 3
      • Saijyo, Japonia
        • Boehringer Ingelheim Investigational Site
      • Saitama, Japonia
        • Boehringer Ingelheim Investigational Site
      • Sakai, Japonia
        • Boehringer Ingelheim Investigational Site 1
      • Sakai, Japonia
        • Boehringer Ingelheim Investigational Site 2
      • Sapporo, Japonia
        • Boehringer Ingelheim Investigational Site 3
      • Sapporo, Japonia
        • Boehringer Ingelheim Investigational Site 4
      • Sapporo, Japonia
        • Boehringer Ingelheim Investigational Site 5
      • Sapporo, Japonia
        • Boehringer Ingelheim Investigational Site 6
      • Sapporo, Japonia
        • Boehringer Ingelheim Investigational Site 8
      • Sapporo, Japonia
        • Boehringer Ingelheim Investigational Site 9
      • Sapporo, Japonia
        • Boehringer Ingelheim Investigational Site 7
      • Sapporo, Japonia
        • Boehringer Ingelheim Investigational Site 1
      • Sapporo, Japonia
        • Boehringer Ingelheim Investigational Site 2
      • Sekigahara, Japonia
        • Boehringer Ingelheim Investigational Site
      • Sendai, Japonia
        • Boehringer Ingelheim Investigational Site 1
      • Sendai, Japonia
        • Boehringer Ingelheim Investigational Site 2
      • Shimoda, Japonia
        • Boehringer Ingelheim Investigational Site
      • Shimotsuke, Japonia
        • Boehringer Ingelheim Investigational Site 1
      • Shimotsuke, Japonia
        • Boehringer Ingelheim Investigational Site 2
      • Shinngu, Japonia
        • Boehringer Ingelheim Investigational Site
      • Shiroishi, Japonia
        • Boehringer Ingelheim Investigational Site
      • Shizuoka, Japonia
        • Boehringer Ingelheim Investigational Site 1
      • Shizuoka, Japonia
        • Boehringer Ingelheim Investigational Site 2
      • Showajima, Japonia
        • Boehringer Ingelheim Investigational Site
      • Suita, Japonia
        • Boehringer Ingelheim Investigational Site 1
      • Suita, Japonia
        • Boehringer Ingelheim Investigational Site 2
      • Susono, Japonia
        • Boehringer Ingelheim Investigational Site
      • Suzuka, Japonia
        • Boehringer Ingelheim Investigational Site
      • Takaoka, Japonia
        • Boehringer Ingelheim Investigational Site 1
      • Takaoka, Japonia
        • Boehringer Ingelheim Investigational Site 2
      • Takatsuki, Japonia
        • Boehringer Ingelheim Investigational Site
      • Tarimizu, Japonia
        • Boehringer Ingelheim Investigational Site
      • Togitsu, Japonia
        • Boehringer Ingelheim Investigational Site
      • Tokoname, Japonia
        • Boehringer Ingelheim Investigational Site
      • Tokushima, Japonia
        • Boehringer Ingelheim Investigational Site
      • Tokyo Arakawa-ku, Japonia
        • Boehringer Ingelheim Investigational Site
      • Tokyo Bunkyo-ku, Japonia
        • Boehringer Ingelheim Investigational Site
      • Tokyo Chuo-ku, Japonia
        • Boehringer Ingelheim Investigational Site 1
      • Tokyo Chuo-ku, Japonia
        • Boehringer Ingelheim Investigational Site 2
      • Tokyo Daito-ku, Japonia
        • Boehringer Ingelheim Investigational Site
      • Tokyo Koto-ku, Japonia
        • Boehringer Ingelheim Investigational Site
      • Tokyo Meguro-ku, Japonia
        • Boehringer Ingelheim Investigational Site 1
      • Tokyo Meguro-ku, Japonia
        • Boehringer Ingelheim Investigational Site 2
      • Tokyo Minato-ku, Japonia
        • Boehringer Ingelheim Investigational Site 1
      • Tokyo Minato-ku, Japonia
        • Boehringer Ingelheim Investigational Site 2
      • Tokyo Minato-ku, Japonia
        • Boehringer Ingelheim Investigational Site 3
      • Tokyo Nakano-ku, Japonia
        • Boehringer Ingelheim Investigational Site
      • Tokyo Nerima-ku, Japonia
        • Boehringer Ingelheim Investigational Site
      • Tokyo Ota-ku, Japonia
        • Boehringer Ingelheim Investigational Site 1
      • Tokyo Ota-ku, Japonia
        • Boehringer Ingelheim Investigational Site 2
      • Tokyo Setagaya, Japonia
        • Boehringer Ingelheim Investigational Site
      • Tokyo Setagaya-ku, Japonia
        • Boehringer Ingelheim Investigational Site
      • Tokyo Shibuya-ku, Japonia
        • Boehringer Ingelheim Investigational Site
      • Tokyo Shinagawa-ku, Japonia
        • Boehringer Ingelheim Investigational Site
      • Tokyo Shinjyuku-ku, Japonia
        • Boehringer Ingelheim Investigational Site 1
      • Tokyo Shinjyuku-ku, Japonia
        • Boehringer Ingelheim Investigational Site 2
      • Tokyo Shinjyuku-ku, Japonia
        • Boehringer Ingelheim Investigational Site 3
      • Tokyo Sibuya-ku, Japonia
        • Boehringer Ingelheim Investigational Site
      • Tokyo Toshima-ku, Japonia
        • Boehringer Ingelheim Investigational Site
      • Tokyo-Edogawa-ku, Japonia
        • Boehringer Ingelheim Investigational Site
      • Tokyo-Itabashi-ku, Japonia
        • Boehringer Ingelheim Investigational Site
      • Toride, Japonia
        • Boehringer Ingelheim Investigational Site
      • Tosu, Japonia
        • Boehringer Ingelheim Investigational Site
      • Toyama, Japonia
        • Boehringer Ingelheim Investigational Site 1
      • Toyama, Japonia
        • Boehringer Ingelheim Investigational Site 2
      • Toyama, Japonia
        • Boehringer Ingelheim Investigational Site 3
      • Toyohashi, Japonia
        • Boehringer Ingelheim Investigational Site
      • Toyokawa, Japonia
        • Boehringer Ingelheim Investigational Site
      • Toyonaka, Japonia
        • Boehringer Ingelheim Investigational Site
      • Ube, Japonia
        • Boehringer Ingelheim Investigational Site
      • Uchinada, Japonia
        • Boehringer Ingelheim Investigational Site
      • Ueda, Japonia
        • Boehringer Ingelheim Investigational Site
      • Ushiku, Japonia
        • Boehringer Ingelheim Investigational Site
      • Utsunomiya, Japonia
        • Boehringer Ingelheim Investigational Site 1
      • Utsunomiya, Japonia
        • Boehringer Ingelheim Investigational Site 2
      • Wakayama, Japonia
        • Boehringer Ingelheim Investigational Site
      • Yachiyo, Japonia
        • Boehringer Ingelheim Investigational Site 1
      • Yachiyo, Japonia
        • Boehringer Ingelheim Investigational Site 2
      • Yachiyo, Japonia
        • Boehringer Ingelheim Investigational Site 3
      • Yamanashi, Japonia
        • Boehringer Ingelheim Investigational Site
      • Yanago, Japonia
        • Boehringer Ingelheim Investigational Site
      • Yoichi, Japonia
        • Boehringer Ingelheim Investigational Site
      • Yokohama, Japonia
        • Boehringer Ingelheim Investigational Site 1
      • Yokohama, Japonia
        • Boehringer Ingelheim Investigational Site 2
      • Yokohama, Japonia
        • Boehringer Ingelheim Investigational Site 3
      • Yokohama, Japonia
        • Boehringer Ingelheim Investigational Site 4
      • Yokosuka, Japonia
        • Boehringer Ingelheim Investigational Site
      • Yoshinogawa, Japonia
        • Boehringer Ingelheim Investigational Site

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

20 lat i starsze (Dorosły, Starszy dorosły)

Akceptuje zdrowych ochotników

Nie

Płeć kwalifikująca się do nauki

Wszystko

Metoda próbkowania

Próbka bez prawdopodobieństwa

Badana populacja

PD patients with depressive symptoms

Opis

Inclusion criteria:

**PD patients with depressive symptoms Patients who have not received pramipexole hydrochloride hydrate preparations within 1 month before survey entrance.

Exclusion criteria:

  • PD patients with the past history of suicidal attempt, suicidal ideation or tendency
  • PD patients with suicidal ideation
  • PD patients with the past history of suicidal tendency

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

Kohorty i interwencje

Grupa / Kohorta
BI-Sifrol® Tablets (Pramipexole)
BI-Sifrol® Tablets, pramipexole dose: 0.125 mg, 0.5 mg, No reference therapy

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Percentage of Participants With Adverse Events, Adverse Drug Reactions, and Serious Adverse Events
Ramy czasowe: for 12 weeks
The aim of this Post Marketing Surveillance (PMS) was to obtain safety data with treatment of pramipexole in Parkinson's disease patients with depressive symptoms. The percentage of participants with adverse events, adverse drug reactions, and serious adverse events are presented.
for 12 weeks

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Clinical Global Impression of Improvement
Ramy czasowe: for 12 weeks after initiation of the treatment
Investigators evaluation of the Parkinson's disease (PD) symptoms on the Clinical Global Impression (CGI) with 5 categories (very much improved, much improved, minimally improved, no effect, and unassessable).
for 12 weeks after initiation of the treatment
Mean Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Part III Total Score
Ramy czasowe: Baseline and after 12 weeks (or at the time of discontinuation)
Part III of the UPDRS contains the clinician-scored motor evaluation, and includes 14 individual items each scored from 0 (Normal) to 4 (Extreme dysfunction). The total score ranged from 0 to 56. A negative change in the Part III total score indicates improvement.
Baseline and after 12 weeks (or at the time of discontinuation)
Mean Change From Baseline in Beck's Depression Inventory (BDI) Total Score
Ramy czasowe: Baseline and after 12 weeks (or at the time of discontinuation)
The degree of severity in depressive state are scored between 0-63 in BDI. A decrease in the score means improvement.
Baseline and after 12 weeks (or at the time of discontinuation)
Mean Change From Baseline in UPDRS (Unified Parkinson's Disease Rating Scale) Part I Item 3 Score
Ramy czasowe: Baseline and after 12 weeks (or at the time of discontinuation)
Unified Parkinson's Disease Rating Scale Part I Item 3 assesses the participant for symptoms of depression. Item 3 scores range from 0 (None) to 4 (Sustained depression with suicidal thoughts or intent). A higher score indicates more severe depression symptoms. A negative change in the item 3 score indicates improvement.
Baseline and after 12 weeks (or at the time of discontinuation)
Mean Change From Baseline in Modified Hoehn & Yahr Rating Scale
Ramy czasowe: After 12 weeks or at the time of discontinuation
This scale is an investigator-completed assessment of the degree of complications arising from Parkinson's disease. The scale ranges from 0 (No signs) to 5 (Bedridden). A negative change in the Yahr rating scale indicates improvement.
After 12 weeks or at the time of discontinuation

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Sponsor

Boehringer Ingelheim

Publikacje i pomocne linki

Osoba odpowiedzialna za wprowadzenie informacji o badaniu dobrowolnie udostępnia te publikacje. Mogą one dotyczyć wszystkiego, co jest związane z badaniem.

Przydatne linki

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów

1 stycznia 2007

Zakończenie podstawowe (Rzeczywisty)

1 sierpnia 2009

Daty rejestracji na studia

Pierwszy przesłany

31 stycznia 2008

Pierwszy przesłany, który spełnia kryteria kontroli jakości

12 lutego 2008

Pierwszy wysłany (Oszacować)

13 lutego 2008

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Oszacować)

6 sierpnia 2014

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

1 sierpnia 2014

Ostatnia weryfikacja

1 sierpnia 2014

Więcej informacji

Terminy związane z tym badaniem

Dodatkowe istotne warunki MeSH

Inne numery identyfikacyjne badania

  • 248.635

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Badania kliniczne na Choroba Parkinsona

Wyszukaj podobne próby

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

CROs by country

CROs in Benin

Warunki

Rzadkie choroby

Interwencje lekowe

Suplementy diety

Sponsor / Współpracownicy

Lokalizacje

3
Subskrybuj